Navigating Late-Stage Colon and Gastrointestinal Cancers

Test ordering is for licensed physicians only.

For Late-Stage Patients and their Oncologists looking for effective Treatments Now

Travera EarlyAccess™ is also available through a no-cost, nationwide clinical study, and other financial assistance is available. To learn if you qualify, use this form or call 781-874-0808.

Colon and Gastrointestinal cancers are particularly challenging diseases that often go undetected until they reach an advanced stage. For those grappling with late-stage colon and GI cancers, standard treatments like surgery, chemotherapy, and targeted therapy may have limited effectiveness.

However, alternative therapeutic options can enhance patients' quality of life, extend survival, and instill hope: ex-vivo cancer drug testing is an increasingly practical approach for individuals seeking effective late-stage ovarian cancer treatments.

Watch the video or keep reading to learn how Ex-Vivo Cancer Drug Testing can evaluate a broad range of FDA-approved drug options and assess their potential for treating your unique cancer.

How it works

Late-stage cancer patients have typically failed ALL of the highly effective drugs given to earlier patients. They are then faced with a long list of less effective drugs, typically with population response rates of around 20%.

But for each patient, it's VERY likely that, “hidden” within that long list of low-effectiveness drugs, a few drugs will be HIGHLY EFFECTIVE for that unique patient.

At Travera, we have solved this problem. We have developed a new method for directly testing a late-stage patient's LIVE cancer cells against long lists of drugs to find any personalized, effective drugs.

In early studies of over 50 cancer patients, the predictive accuracy of our test is around 80%, across virtually all cancers, including ovarian cancer.

This is a game changer for the millions of late-stage cancer patients seeking to add quality months or years to their lives. And for oncologists, our unique test enables them to deliver the right drug to the right patient at the right time.

See also

Learn More About our Tests

Travera EarlyAccess™

Travera EarlyAccess™ tests live cancer cells against a predetermined panel of 20 FDA-approved cancer drugs. This option requires that you share the treatment outcome data to help Travera build additional clinical evidence.

  • Turnaround time: 2 days from sample collection

  • Total drugs tested: 20 FDA-approved

  • Sample types: Tissue, Malignant Fluids

Travera RTS™

Travera RTS™ tests live cancer cells against a panel of up to 20 FDA-approved cancer drugs of your choice. Our catalog includes over 100 FDA-approved drugs.

  • Turnaround time: 2 days from sample collection

  • Total drugs tested: up to 20 FDA-approved

  • Sample types: Tissue, Malignant Fluids

If you are interested in learning more, please contact us online or call us at 781-874-0808.

Travera EarlyAccess™ is also available through a no-cost, nation-wide clinical study, and other financial assistance is available.
To learn if you qualify, use this form or call 781-874-0808.

Travera EarlyAccess™ for Colon and Gastrointestinal Cancers tests the following drugs:

NCCN Inhibitors

  1. Encorafenib (Braftovi)

  2. Entrectinib (Rozlytrek)

  3. Lapatinib (Tykerb)

  4. Larotrectinib (Vitrakvi)

  5. Regorafenib (Stivarga)

NCCN Chemotherapies

  1. FOLFIRI

  2. FOLFOX

  3. Irinotecan (Camptosar)

  4. Oxaliplatin (Eloxatin)

  5. Tipiracil (Lonsurf)

Off-label Inhibitors

  1. Binimetinib (Mektovi)

  2. Dasatinib (Sprycel)

  3. Everolimus (Afinitor)

  4. Imatinib (Gleevec)

  5. Olaparib (Lynparza)

  6. Ponatinib (Iclusig)

  7. Sunitinib (Sutent)

  8. Trametinib (Mekinist)

  9. Vincristine (Oncovin)

  10. Vandetanib (Caprelsa)